These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Synthesis of novel phenylalanine-coated copper nanoclusters for fluorescent probes to determine the interactions of cancer drugs with DNA.
    Author: Bilkay M, Satana Kara HE.
    Journal: J Pharm Biomed Anal; 2024 Oct 15; 249():116365. PubMed ID: 39024792.
    Abstract:
    Abiraterone acetate (ATA) is an FDA-approved prodrug that exerts its effects by irreversibly inhibiting the enzymatic activities of 17α-hydroxylase and C17,20-lyase, which are responsible for testosterone production, particularly. Drug-DNA interaction studies are conducted using various methods. In this study, CuNCs were used as a fluorescent probe for the first time to investigate drug-DNA interactions. Additionally, a new synthesis was developed for copper nanoclusters coated with phenylalanine (Phe). Ascorbic acid served as the reducing agent, while Phe was used as a surface functionalizing and stabilizing agent. Phe/CuNCs were characterized using various techniques including TEM, DLS, XPS, UV-Vis spectroscopy, and fluorescence spectroscopy. Optimization studies were conducted for synthesis parameters such as ascorbic acid concentration, Phe concentration, incubation time, and incubation temperature. This new synthesis method offers various advantages such as easy synthesis procedure, short synthesis time, and compatibility with green chemistry principles. Phe/CuNCs were used as a fluorescent probe for ATA-DNA interactions. The binding constant (Ka) between ATA and DNA was calculated as 1.03 × 104. Furthermore, thermodynamic studies indicated that the effective forces involved in ATA-DNA interaction are Van der Waals and hydrogen bonding.
    [Abstract] [Full Text] [Related] [New Search]